Mumbai, Oct 18: Pharma major Glenmark Pharma announced on Wednesday that it has launched in India the first triple-drug fixed-dose combination (FDC) of the widely used Teneligliptin with Dapagliflozin and Metformin.
This FDC has been launched under the brand name Zita DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin (10mg), and Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with type 2 diabetes.
On the occasion of the launch, Alok Malik, President and Business Head, India Formulations, Glenmark Pharma, stated, “India has the second-largest diabetic population in the world, and Type 2 diabetic patients here often face issues of uncontrolled hemoglobin A1C (HbA1Ci), beta cell dysfunction, which impairs insulin secretion, along with other co-morbidities like weight gain.
Diabetes management, therefore, becomes difficult for these patients and a challenge for healthcare providers. Being a leader in treating diabetes, we are proud to introduce Zita DM, a novel and affordable anti-diabetic drug that helps improve glycemic control among adult patients with high HbA1c and other co-morbidities while also reducing major renal and cardiac adverse events. With this robust profile, we are positive Zita DM will facilitate patient adherence to chronic diabetes treatments.”
Glenmark’s Zita portfolio of medicines has been benefiting around 1.75 million Type 2 diabetic patients annually in India. With the launch of Zita DM, Zita the most comprehensive gliptin range now holds promise of helping Type 2 diabetic patients at every stage of their treatment.
According to IQVIA sales data for the 12-month period ending August 2023 (MAT August 2023), the market for oral anti-diabetic drugs in India is estimated to be Rs 12,522 crore.
